Abstract
The management of neuropathic pain remains very challenging and very much an art. Despite the publication of multiple consensus guidelines on the management of neuropathic pain, a significant subpopulation of patients with neuropathic pain are not afforded adequate relief, employing various treatment algorithms with conventional pharmacological therapeutic strategies. First-line agents for the treatment of neuropathic pain include: tricyclic antidepressants, selective serotonin/norepinephrine re-uptake inhibitors, calcium channel α2-δ ligands and, in certain cases of focal neuropathic pain, a lidocaine patch. Novel analgesics under development may include: purinergic receptor modulators, cannabinoid receptor modulators, neurokinin-1 (NK-1) receptor modulators, glial modulators, rostral ventral medulla 'on-cell' modulators, chemokine receptor modulators, toll-like receptor modulators, modulators of tetrahydrobiopterin synthesis and/or chemically re-engineered conotoxins. It is hoped that future agents and/or combinations of agents may be helpful to this refractory subpopulation. © TOUCHBRIEFINGS 2012.
Author supplied keywords
Cite
CITATION STYLE
Smith, H. S., Kara, S. D., & Argoff, C. E. (2012). Management of neuropathic pain - Current insights and future perspectives. European Neurological Review, 7(1), 72–75. https://doi.org/10.17925/enr.2012.07.01.72
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.